Summary of CTLA-4 expression in human acute and chronic leukemias
| Leukemia . | ScFv no. (total no.) . | mAb BN13 . | ||||
|---|---|---|---|---|---|---|
| 3 . | 40 . | 55 . | 67 . | 83 . | ||
| AML | ||||||
| Surface | 16 (31) | 22 (31) | 22 (27) | 23 (27) | 23 (31) | 23 (27) |
| Cytoplasm | 30 (31) | 30 (31) | 25 (27) | 25 (27) | 31 (31) | 26 (27) |
| CML | ||||||
| Surface | 1 (4) | 3 (4) | 3 (4) | 4 (4) | 4 (4) | 4 (4) |
| Cytoplasm | 4 (4) | 4 (4) | 4 (4) | 4 (4) | 4 (4) | 4 (4) |
| B-ALL | ||||||
| Surface | 2 (53) | 1 (53) | 1 (12) | 1 (15) | 8 (53) | 2 (10) |
| Cytoplasm | 24 (35) | 7 (35) | 8 (12) | 10 (15) | 34 (35) | 9 (10) |
| T-ALL | ||||||
| Surface | 1 (6) | 1 (6) | 1 (6) | 1 (6) | 1 (6) | 1 (2) |
| Cytoplasm | 2 (3) | 3 (3) | 2 (2) | 2 (2) | 3 (3) | 2 (2) |
| B-CLL | ||||||
| Surface | 3 (4) | 3 (4) | 3 (4) | 3 (4) | 3 (4) | 3 (4) |
| Cytoplasm | 4 (4) | 4 (4) | 4 (4) | 4 (4) | 4 (4) | 4 (4) |
| T-CLL (LGL) | ||||||
| Surface | 0 (2) | 0 (2) | 0 (2) | 0 (2) | 0 (2) | 0 (2) |
| Cytoplasm | 0 (2) | 0 (2) | 0 (2) | 0 (2) | 0 (2) | 0 (2) |
| Leukemia . | ScFv no. (total no.) . | mAb BN13 . | ||||
|---|---|---|---|---|---|---|
| 3 . | 40 . | 55 . | 67 . | 83 . | ||
| AML | ||||||
| Surface | 16 (31) | 22 (31) | 22 (27) | 23 (27) | 23 (31) | 23 (27) |
| Cytoplasm | 30 (31) | 30 (31) | 25 (27) | 25 (27) | 31 (31) | 26 (27) |
| CML | ||||||
| Surface | 1 (4) | 3 (4) | 3 (4) | 4 (4) | 4 (4) | 4 (4) |
| Cytoplasm | 4 (4) | 4 (4) | 4 (4) | 4 (4) | 4 (4) | 4 (4) |
| B-ALL | ||||||
| Surface | 2 (53) | 1 (53) | 1 (12) | 1 (15) | 8 (53) | 2 (10) |
| Cytoplasm | 24 (35) | 7 (35) | 8 (12) | 10 (15) | 34 (35) | 9 (10) |
| T-ALL | ||||||
| Surface | 1 (6) | 1 (6) | 1 (6) | 1 (6) | 1 (6) | 1 (2) |
| Cytoplasm | 2 (3) | 3 (3) | 2 (2) | 2 (2) | 3 (3) | 2 (2) |
| B-CLL | ||||||
| Surface | 3 (4) | 3 (4) | 3 (4) | 3 (4) | 3 (4) | 3 (4) |
| Cytoplasm | 4 (4) | 4 (4) | 4 (4) | 4 (4) | 4 (4) | 4 (4) |
| T-CLL (LGL) | ||||||
| Surface | 0 (2) | 0 (2) | 0 (2) | 0 (2) | 0 (2) | 0 (2) |
| Cytoplasm | 0 (2) | 0 (2) | 0 (2) | 0 (2) | 0 (2) | 0 (2) |
Reactivity of leukemic cells with a panel of FITC-conjugated anti-CTLA-4 scFvs and the commercial BN13 mAb by flow cytometry. Positivity was considered when the histogram shift of the sample was greater than 1 log relative to the negative control. Data are presented as the number of samples that reacted positively.